Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 16/20 | 0.65 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.65 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295571 | 0.93 | MMP13 (0.56) | MMP13SLC22A8MAPTALDH1A1CYP1A2 | |
| SCHEMBL6468114 | 0.92 | MMP13 (0.67) | MMP13SLC22A8PTGER4MAPT | |
| SCHEMBL6428872 | 0.90 | MMP13 (0.53) | MMP13SLC22A8MAPTALDH1A1CYP1A2 | |
| SCHEMBL6256740 | 0.88 | MMP13 (0.51) | MMP13SLC22A8MAPTALDH1A1CYP1A2 | |
| SCHEMBL6259580 | 0.87 | MMP13 (0.61) | MMP13SLC22A8PTGER4MAPTALDH1A1 | |
| SCHEMBL7100732 | 0.86 | PIK3CD (0.51) | MMP13SLC22A8MAPTALDH1A1L3MBTL1 | |
| SCHEMBL6464565 | 0.84 | MMP13 (0.60) | MMP13SLC22A8PTGER4MAPTALDH1A1 | |
| SCHEMBL7104026 | 0.83 | MMP13 (0.48) | MMP13SLC22A8MAPTALDH1A1CYP1A2 | |
| SCHEMBL7104020 | 0.83 | MMP13 (0.48) | MMP13SLC22A8MAPTALDH1A1CYP1A2 | |
| SCHEMBL6234634 | 0.82 | MMP13 (0.58) | MMP13MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | claimed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | claimed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| US-20050085447-A1 | Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors | WARNER-LAMBERT COMPANY LLC | 2005-04-21 | — | — | US | disclosed |
| WO-2005016926-A1 | PYRIDO [3,4-D] PYRIMIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SLC22A8 315/4885PTGER4 579/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | MMP13 1/4885SLC22A8 1442/4885PTGER4 690/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885SLC22A8 123/4885PTGER4 181/4885 |
| US-20050085447-A1 | Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SLC22A8 2982/4885PTGER4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.